Answers are grounded in this paper and cite their sources.
Metabolic and bioprocess engineering aim to achieve high fermentation titer, rate and yield (TRY), yet no general framework connects these interdependent metrics to facility-scale economics. We introduce NSKinetics, an agile computational framework embedding biochemically structured kinetic models within facility-scale process simulation, techno-economic analysis, uncertainty analysis, global sensitivity analysis, and optimization. We find that for yeast-based ethanol and isobutanol production in a corn biorefinery, cost uncertainty for today's technology is governed by scale, feedstock price, and co-product value rather than ethanol fermentation kinetics. Nonintuitively, while eliminating ethanol inhibition enables a 3.7-fold increase in ethanol productivity, it makes the facility unprofitable by diverting too much carbon to cell growth. Across eight Bayesian optimization campaigns over 12 enzyme-expression, tolerance, and substrate-feeding decisions, TRY-optimized strains were poorly profitable, and a profitability-only campaign stalled at an ethanol-only optimum (15.8% internal rate of return, IRR). However, combining the approaches with a profitability campaign informed by the TRY campaigns' exploration revealed the potential to engineer an ethanol-isobutanol co-producing strain with 27.3% IRR. Fermentation metrics are therefore insufficient proxies for profitability, but valuable guides across the rugged profitability landscape.
No takes yet. Share an insight, caveat, or question.
Bhagwat et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: